The risk stratification in atrial fibrillation

[1]  G. Lip,et al.  Atrial fibrillation , 2012, The Lancet.

[2]  D. Singer,et al.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[3]  G. Lip.  Can We Predict Stroke in Atrial Fibrillation? , 2012, Clinical cardiology.

[4]  B. Dimitrov,et al.  Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke , 2011, Thrombosis and Haemostasis.

[5]  A. Capucci,et al.  Improving Stroke Risk Stratification Using the CHADS2 and CHA2DS2-VASc Risk Scores in Patients With Paroxysmal Atrial Fibrillation by Continuous Arrhythmia Burden Monitoring , 2011, Stroke.

[6]  John Camm,et al.  Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[7]  Jinkwon Kim,et al.  Increases in Cerebral Atherosclerosis According to CHADS2 Scores in Patients With Stroke With Nonvalvular Atrial Fibrillation , 2011, Stroke.

[8]  J. Tolstrup,et al.  Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.

[9]  G. Lip,et al.  Stroke Risk Stratification in a “Real‐World” Elderly Anticoagulated Atrial Fibrillation Population , 2011, Journal of cardiovascular electrophysiology.

[10]  D. Lane,et al.  A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice , 2011, Journal of thrombosis and haemostasis : JTH.

[11]  G. Lip,et al.  Identifying Patients at High Risk for Stroke Despite Anticoagulation: A Comparison of Contemporary Stroke Risk Stratification Schemes in an Anticoagulated Atrial Fibrillation Cohort , 2010, Stroke.

[12]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[13]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[14]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[15]  E. Hylek,et al.  New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs , 2010, Thrombosis and Haemostasis.

[16]  Shen-Chih Chang,et al.  Low glomerular filtration rate and risk of stroke: meta-analysis , 2010, BMJ : British Medical Journal.

[17]  Gregory Y H Lip,et al.  Improving stroke risk stratification in atrial fibrillation. , 2010, The American journal of medicine.

[18]  G. Karthikeyan,et al.  The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe? , 2010, Thrombosis and Haemostasis.

[19]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[20]  Dongfeng Qi,et al.  The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study , 2009, Circulation. Arrhythmia and electrophysiology.

[21]  R. Abbate,et al.  Stroke risk in atrial fibrillation patients on warfarin , 2009, Thrombosis and Haemostasis.

[22]  D. Roden,et al.  Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. , 2009, American heart journal.

[23]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[24]  D. Singer,et al.  Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. , 2008, Journal of the American College of Cardiology.

[25]  Gregory Y H Lip,et al.  Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data , 2008, Thrombosis and Haemostasis.

[26]  G. Lip,et al.  Atrial fibrillation and stroke prevention , 2007, The Lancet Neurology.

[27]  B. Gage,et al.  Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified? , 2007, Stroke.

[28]  Silvia G Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit , 2006, Journal of the American College of Cardiology.

[29]  Samuel Wann,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.

[30]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[31]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[32]  Kiyoshi Yoshida,et al.  Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. , 2006, Stroke.

[33]  R. Abbate,et al.  Culprit Factors for the Failure of Well-Conducted Warfarin Therapy to Prevent Ischemic Events in Patients With Atrial Fibrillation: The Role of Homocysteine , 2005, Stroke.

[34]  D. Wyse,et al.  Management of atrial fibrillation. , 2005, Current problems in cardiology.

[35]  B. Gage,et al.  Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin , 2004, Circulation.

[36]  R. D. Murray,et al.  Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. , 2004, The American journal of cardiology.

[37]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[38]  G. Lip,et al.  Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. , 2004, American heart journal.

[39]  Daniel Levy,et al.  Arrhythmias: abstractA risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study☆ , 2003 .

[40]  A. Laupacis,et al.  A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. , 2003, Archives of internal medicine.

[41]  S. Iliceto,et al.  Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation. , 2002, The American journal of cardiology.

[42]  Natalia S. Rost,et al.  Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study , 2001, Stroke.

[43]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[44]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[45]  李永军,et al.  Atrial Fibrillation , 1999 .

[46]  R McBride,et al.  Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.

[47]  U. Ikeda,et al.  Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1998, American heart journal.

[48]  W. Aronow,et al.  Risk factors for new thromboembolic stroke in patients > or = 62 years of age with chronic atrial fibrillation. , 1998, The American journal of cardiology.

[49]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[50]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[51]  G. Lip,et al.  Physician variation in the management of patients with atrial fibrillation. , 1996, Heart.

[52]  G. Lowe,et al.  ABC of Atrial Fibrillation: ANTITHROMBOTIC TREATMENT FOR ATRIAL FIBRILLATION , 1996, BMJ.

[53]  A. Algra,et al.  Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. , 1995, Stroke.

[54]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[55]  A R Feinstein,et al.  Risk for systemic embolization of atrial fibrillation without mitral stenosis. , 1990, The American journal of cardiology.

[56]  J. Kastrup,et al.  Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. , 1990 .

[57]  W. Aronow,et al.  Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. , 1989, The American journal of cardiology.

[58]  G. Lip,et al.  Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. , 2012, Chest.

[59]  A. Rabinstein.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2010 .

[60]  R. Berg,et al.  A Systematic Review and Meta-analysis , 2010 .

[61]  G. Guyatt,et al.  Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and , 2008 .

[62]  J. Halperin,et al.  Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. , 2000, Journal of the American College of Cardiology.

[63]  D. Singer,et al.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[64]  R. Cheung.  Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. , 1998, JAMA.

[65]  G. Lip.  ABC of atrial fibrillation , 1996 .

[66]  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. , 1994, Archives of internal medicine.